Double-blind, Randomized Controlled Study in Non-Hodgkin's Lymphoma

- DLBCL
- Completed

Study Title: A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

Teva Identifier: NHL-TL011-102

ClinicalTrials.gov Identifier: NCT01205737

Study Status: Completed

Trial Condition(s): DLBCL

Interventions: Biological: TL011 | Biological: Rituximab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years to 80 Years

Trial Duration: 09/01/2010 - 09/01/2013

Phase: Phase 1

Study Type

Interventional